Literature DB >> 24507156

Recognition of tumors by the innate immune system and natural killer cells.

Assaf Marcus1, Benjamin G Gowen1, Thornton W Thompson1, Alexandre Iannello1, Michele Ardolino1, Weiwen Deng1, Lin Wang1, Nataliya Shifrin1, David H Raulet2.   

Abstract

In recent years, roles of the immune system in immune surveillance of cancer have been explored using a variety of approaches. The roles of the adaptive immune system have been a major emphasis, but increasing evidence supports a role for innate immune effector cells such as natural killer (NK) cells in tumor surveillance. Here, we discuss some of the evidence for roles in tumor surveillance of innate immune cells. In particular, we focus on NK cells and other immune cells that express germline-encoded receptors, often labeled NK receptors. The impact of these receptors and the cells that express them on tumor suppression is summarized. We discuss in detail some of the pathways and events in tumor cells that induce or upregulate cell-surface expression of the ligands for these receptors, and the logic of how those pathways serve to identify malignant, or potentially malignant cells. How tumors often evade tumor suppression mediated by innate killer cells is another major subject of the review. We end with a discussion on some of the implications of the various findings with respect to possible therapeutic approaches.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; DNA-damage response; DNAM-1; Immunoediting; Innate immunity; NKG2D; Proliferation; Senescence; Tumor immunosurveillance

Mesh:

Substances:

Year:  2014        PMID: 24507156      PMCID: PMC4228931          DOI: 10.1016/B978-0-12-800267-4.00003-1

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  201 in total

Review 1.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.

Authors:  Hai Li; Tadepally Lakshmikanth; Cinzia Garofalo; Martin Enge; Clemens Spinnler; Andrea Anichini; Laszlo Szekely; Klas Kärre; Ennio Carbone; Galina Selivanova
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

4.  Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome.

Authors:  S G Tangye; J H Phillips; L L Lanier; K E Nichols
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

5.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.

Authors:  Tae-Won Kang; Tetyana Yevsa; Norman Woller; Lisa Hoenicke; Torsten Wuestefeld; Daniel Dauch; Anja Hohmeyer; Marcus Gereke; Ramona Rudalska; Anna Potapova; Marcus Iken; Mihael Vucur; Siegfried Weiss; Mathias Heikenwalder; Sadaf Khan; Jesus Gil; Dunja Bruder; Michael Manns; Peter Schirmacher; Frank Tacke; Michael Ott; Tom Luedde; Thomas Longerich; Stefan Kubicka; Lars Zender
Journal:  Nature       Date:  2011-11-09       Impact factor: 49.962

6.  BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.

Authors:  Nicolas Boissel; Delphine Rea; Vannary Tieng; Nicolas Dulphy; Manuel Brun; Jean-Michel Cayuela; Philippe Rousselot; Ryad Tamouza; Philippe Le Bouteiller; François-Xavier Mahon; Alexander Steinle; Dominique Charron; Hervé Dombret; Antoine Toubert
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Authors:  Manuel A Friese; Michael Platten; Stefan Z Lutz; Ulrike Naumann; Steffen Aulwurm; Felix Bischof; Hans-Jörg Bühring; Johannes Dichgans; Hans-Georg Rammensee; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

8.  TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors.

Authors:  G F Burns; T Triglia; J A Werkmeister; C G Begley; A W Boyd
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

9.  Accelerated tumor growth in mice deficient in DNAM-1 receptor.

Authors:  Akiko Iguchi-Manaka; Hirayasu Kai; Yumi Yamashita; Kai Shibata; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Teruhito Yasui; Hitoshi Kikutani; Kazuko Shibuya; Akira Shibuya
Journal:  J Exp Med       Date:  2008-11-24       Impact factor: 14.307

10.  Gamma delta T cells provide an early source of interferon gamma in tumor immunity.

Authors:  Yunfei Gao; Wancai Yang; Meng Pan; Eileen Scully; Michael Girardi; Leonard H Augenlicht; Joe Craft; Zhinan Yin
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  144 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Dysregulation of TLR9 in neonates leads to fatal inflammatory disease driven by IFN-γ.

Authors:  Alison G Stanbery; Zachary R Newman; Gregory M Barton
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205

3.  Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis.

Authors:  Alejandro Torres-Hernandez; Wei Wang; Yuri Nikiforov; Karla Tejada; Luisana Torres; Aleksandr Kalabin; Yue Wu; Muhammad Israr Ul Haq; Mohammed Y Khan; Zhen Zhao; Wenyu Su; Jimmy Camargo; Mautin Hundeyin; Brian Diskin; Salma Adam; Juan A Kochen Rossi; Emma Kurz; Berk Aykut; Sorin A A Shadaloey; Joshua Leinwand; George Miller
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

4.  NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.

Authors:  Meriem Messaoudene; Giulia Fregni; David Enot; Nicolas Jacquelot; Emmanuelle Neves; Nathalie Germaud; Henri Jean Garchon; Wahid Boukouaci; Ryad Tamouza; Johan Chanal; Marie-Françoise Avril; Antoine Toubert; Laurence Zitvogel; Sylvie Rusakiewicz; Anne Caignard
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

5.  Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.

Authors:  Li Wenbo; Jin Wang
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

6.  Baculovirus directly activates murine NK cells via TLR9.

Authors:  T Moriyama; T Suzuki; M O Chang; M Kitajima; H Takaku
Journal:  Cancer Gene Ther       Date:  2017-02-10       Impact factor: 5.987

7.  NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline.

Authors:  Andrew R Osterburg; Rebecca L Nelson; Benyamin Z Yaniv; Rachel Foot; Walter Rf Donica; Madison A Nashu; Huan Liu; Kathryn A Wikenheiser-Brokamp; Joel Moss; Nishant Gupta; Francis X McCormack; Michael T Borchers
Journal:  JCI Insight       Date:  2016-10-06

8.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Authors:  Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

9.  SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling.

Authors:  Victor S Cortez; Tyler K Ulland; Luisa Cervantes-Barragan; Jennifer K Bando; Michelle L Robinette; Qianli Wang; Andrew J White; Susan Gilfillan; Marina Cella; Marco Colonna
Journal:  Nat Immunol       Date:  2017-07-31       Impact factor: 25.606

10.  Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors:  Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.